CAR-T Therapy Cost 2026: US vs China vs Korea vs Turkey ($30K-$475K)
cancercaree.com
Nov. 21, 2026, 5:12 a.m.
# Professional Summary
This comprehensive health-economics analysis examines the true total cost of care (TCOC) for CAR-T cell therapy across seven countries, challenging the common misconception that significant savings justify international travel for treatment. The study demonstrates that while base drug costs vary substantially—from approximately $30,000–$80,000 in China to $400,000 in the United States—the actual financial differential shrinks dramatically when accounting for hidden expenses including six to eight weeks of international accommodation, companion travel costs, potential intensive care management of Cytokine Release Syndrome, and lost income. The realistic cost disparity between countries typically amounts to 60–70%, not the 90% commonly cited. The analysis employs rigorous health-economics methodology, including incremental cost-effectiveness ratio calculations (ICER), establishing that ratios below $100,000–$150,000 per quality-adjusted life year generally represent cost-effective interventions. Critical barriers to cross-border CAR-T therapy include clinical-trial eligibility requirements, visa processing delays of 4–8 weeks, disease urgency, patient mobility constraints, and mandatory companion care requirements. The research emphasizes that clinical trial screening and logistical considerations often represent the primary financial gatekeepers, superseding simplified drug-cost comparisons. Financial optimization should never compromise clinical safety or introduce treatment delays in rapidly progressing malignancies.